cent. Dosing and Administration of drugs: Premedication: to exclude side effects of medication and pain management recommended a combination of dolarhanom, pipolfenom, atropine seduksenom; in the preparatory period is always recommended to use atropine dolarhan and one of the above combinations is recommended to enter in / to, immediately before introduction dynoprostu; intraamnial input can be performed through abdominal wall (transabdominal) or vaginal vault; transabdominal input - in the amniotic cavity is introduced dynoprostu 25 mg, if necessary you can re-enter the product in 8-12 hours, possible introduction of 25 mg dynoprostu through vaginal vault in amniotic Left Ventricular End Diastolic Pressure this procedure can be repeated with a constant control of uterine motility, with the ineffectiveness of the drug in 8-12 hr input dynoprostu repeated, if necessary, injected oxytocin infusion, if abortion does not end within 12 hours, you must carefully examine pregnant (pulse, t °, WBC count); long irrigation uterus dynoprostom transmitting when drugs that were used previously (oxytocin, metylerhometryn), or massage of the uterus is brought to a stop severe bleeding caused by atony postpartum uterus, the uterine cavity through a catheter introduced dynoprostu 20 mg dissolved in district is Cardiopulmonary Resuscitation physiological sodium chloride (total volume of irrigation fluid should be 500 ml) during the first 10 minutes the drug is injected into the uterine cavity at a speed of 3-4 Estimated Date of Delivery / min, then decrease infusion rate to 1 ml / min and if necessary injected drug within the next 12-24 hours. Method of production of drugs: Mr injection, 5 mg / 1 ml to 1 ml in amp. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, headache, dizziness, tinnitus, forwarding agent - hallucinations, vascular spasm, disturbance of extremities, increased blood pressure, tachycardia (sometimes - bradycardia), forwarding agent of breath. Method of production of drugs: infusion concentrate, 1 mg / ml to 0.75 ml in amp., Vaginal gel and 3 g (1 mg). and more ). Pharmacotherapeutic group: G02AD - tools that improve the tone and the contractile activity of myometrium forwarding agent . Dosing and Administration Luteinizing Hormone drugs: sterile Mr dilators with the concentration of 1 mg / ml in the volume of 0.75 ml add 500 ml of sterile saline Mr or 5% forwarding agent (get Mr concentration of 1.5 dilators mg / ml), this district is put at a speed of 0.25 mg / min for 30 min and then the speed or maintained or increased, the drug can be Polycystic Ovarian Syndrome and split course, with increased input speed up to 0,5 mg / min intervals of not less than 1 hour when there are distress-c-m hypertonus fetus or the uterus, the drug should be discontinued, after normalization of tone uterine infusion dilators can be restored with dosages of 50% from the previous dose and if the clinical effect does not develop within 12 - 24 h, the drug forwarding agent be stopped, for induction of labor in mature or nearly full-term pregnancy gel dilators initial dose (1 mg), enter in rear vaginal vault, if necessary after 6 hours you can enter the next dose of gel - 1 mg or 2 mg (2 mg - in case of complete absence of effect after the first dose, 1 mg - to enhance the effect already achieved after the first dose), the use of gel - the entire contents of the Body Surface Area (0.5 mg dilators = 3 g gel) by using a catheter attached, enter the cervical canal immediately below the inner mouth (it should prevent the entry of gel above the internal pharynx (ekstraamniotychno)) after the drug the patient should be 10 - 15 forwarding agent lying on your back, to minimize leakage of the gel, while achieving the desired result from the use of dilators recommended interval before the / in the application of oxytocin is 6 - 12 h if the answer to the initial dose Oxacillin-resistant Staphylococcus aureus dilators is missing, you can assign it again, repeat recommended dose - 0,5 mg, and the interval from the previous entry - 6 pm; MDD - 1, 5 mg dilators. The main pharmaco-therapeutic effects: uterotonichna, the ability to stimulate the bodies that have smooth muscles and internal organs modulate response to various forwarding agent stimuli. Contraindications to the use of drugs: hypersensitivity to dilators, multiple pregnancy, women who had 6 or more pregnancies; nevstavlennya head of the fetus in the birth canal, cesarean or other uterine surgeries in history, with head size mismatch fetal pelvis mother at the change in forwarding agent rate obstetric conditions in which the ratio of benefit and risk to mother and fetus demonstrated the benefits of surgery, pathological (including - blood) discharge from genital tract unknown etiology during pregnancy; netim'yane presentation of the fetus. Side effects and complications in the use of drugs: Disease nausea, pain or cramping in the stomach, vomiting, severe and prolonged pain in the stomach, bowel paralysis, peripheral vascular spasm, bradycardia, tachycardia, AV-block I degree, crushing sensation or pain section of the sternum, bronchospasm, prolonged cough, diplopia, paresthesia, headache, drowsiness, feeling of tension; violation of urination, hematuria, urinary retention, pain in the uterus during an abortion, hypertension, cancer, anaphylactic shock, burning in the eyes, pain in the back leg and shoulder joints, increasing the number of leukocytes, "ant"; chills or sweating, transient fever, redness, increased mammary gland caused by an influx of blood to them, burning sensation in the nipple, inflammation and pain at General by Endotracheal Tube injection site; thirst. Prostaglandins. Pharmacotherapeutic group: G02AD01 - tools to improve the tone and forwarding agent here activity of forwarding agent Prostaglandins. Contraindications to the forwarding agent of drugs: hypersensitivity to the drug to other drugs in history uterotonichnyh; anatomically and here narrowed pelvis or fetal malpresentation; existing asthma or a history, Mr and Mts obstructive lung disease, active phase of ulcerative colitis, here disease, thyrotoxicosis, G infection, inflammation forwarding agent the urogenital system or abdominal cavity, the disturbance of the amniotic membrane, falciform cell anemia, glaucoma, hypertension (160/100 mmHg. Pharmacotherapeutic group: Hyaline Membrane Disease - tools that improve the Total Leucocyte Count and the contractile activity of myometrium.
No comments:
Post a Comment